Balchem (BCPC) SVP granted 2,500 restricted stock on 10/20/2025
Balchem Corp (BCPC) reported that its SVP and Chief R&D Officer acquired 2,500 shares of common stock on 10/20/2025 via a restricted stock grant at $0 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Balchem Corp (BCPC) reported that its SVP and Chief R&D Officer acquired 2,500 shares of common stock on 10/20/2025 via a restricted stock grant at $0 per share. Following the transaction, the reporting person beneficially owns 2,500 shares, held directly.
The award vests ratably over three years—25% on the first anniversary, 25% on the second, and 50% on the third—subject to transfer restrictions under a Restricted Stock Grant Agreement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,500 | $0.00 | $0.00 |
Footnotes (1)
- F1. Ownership of restricted stock vests in Reporting Person ratably over a 3 year period (25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 50% on the third anniversary of the grant date), subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Balchem (BCPC) disclose in this Form 4?
Who is the reporting person in the BCPC filing?
What is the ownership form after the transaction for BCPC?
Is the BCPC grant subject to restrictions?
What transaction code appears in the BCPC Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.